Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer's disease.
Aged
Aged, 80 and over
Alzheimer Disease
/ complications
Apolipoproteins E
/ genetics
Area Under Curve
Base Sequence
Biomarkers
/ blood
Cardiovascular Diseases
/ complications
Case-Control Studies
Cognitive Dysfunction
/ diagnosis
DNA Methylation
Dementia, Vascular
/ complications
Female
Genotype
Humans
Male
Promoter Regions, Genetic
ROC Curve
Severity of Illness Index
Transferases
/ blood
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 07 2020
22 07 2020
Historique:
received:
24
03
2020
accepted:
07
07
2020
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Early diagnosis of dementia including Alzheimer's disease (AD) is an urgent medical and welfare issue. However, to date, no simple biometrics have been available. We reported that blood DNA methylation levels of the COASY gene, which encodes coenzyme A synthase, were increased in individuals with AD and amnestic mild cognitive impairment (aMCI). The present study sought to replicate these findings with larger numbers of samples. Another objective was to clarify whether COASY methylation is associated with neurodegeneration through a comparison of AD, AD with cardiovascular disease (CVD), and vascular dementia (VaD). We measured blood COASY methylation levels in normal controls (NCs) (n = 200), and individuals with aMCI (n = 22), AD (n = 151), and VaD (n = 21). Compared with NCs, they were significantly higher in individuals with aMCI and AD. Further, they were significantly higher in AD patients without cardiovascular diseases compared to AD patients with them. These findings suggest that COASY methylation levels may be related to neurodegeneration in AD.
Identifiants
pubmed: 32699290
doi: 10.1038/s41598-020-69248-9
pii: 10.1038/s41598-020-69248-9
pmc: PMC7376092
doi:
Substances chimiques
Apolipoproteins E
0
Biomarkers
0
Transferases
EC 2.-
COASY protein, human
EC 2.7.7.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12217Références
McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia J. Alzheimer’s Assoc. 7, 263–269. https://doi.org/10.1016/j.jalz.2011.03.005 (2011).
doi: 10.1016/j.jalz.2011.03.005
O’Brien, J. T. & Thomas, A. Vascular dementia. Lancet 386, 1698–1706. https://doi.org/10.1016/S0140-6736(15)00463-8 (2015).
doi: 10.1016/S0140-6736(15)00463-8
pubmed: 26595643
Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608. https://doi.org/10.15252/emmm.201606210 (2016).
doi: 10.15252/emmm.201606210
pubmed: 27025652
pmcid: 4888851
Feil, R. & Fraga, M. F. Epigenetics and the environment: emerging patterns and implications. Nat. Rev. Genet. 13, 97–109. https://doi.org/10.1038/nrg3142 (2012).
doi: 10.1038/nrg3142
pubmed: 22215131
Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115. https://doi.org/10.1186/gb-2013-14-10-r115 (2013).
doi: 10.1186/gb-2013-14-10-r115
pubmed: 24138928
pmcid: 4015143
Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 49, 359–367. https://doi.org/10.1016/j.molcel.2012.10.016 (2013).
doi: 10.1016/j.molcel.2012.10.016
pubmed: 23177740
Fransquet, P. D. et al. Blood DNA methylation as a potential biomarker of dementia: a systematic review. Alzheimer’s Dementia J. Alzheimer’s Assoc. 14, 81–103. https://doi.org/10.1016/j.jalz.2017.10.002 (2018).
doi: 10.1016/j.jalz.2017.10.002
Dusi, S. et al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 94, 11–22. https://doi.org/10.1016/j.ajhg.2013.11.008 (2014).
doi: 10.1016/j.ajhg.2013.11.008
pubmed: 24360804
pmcid: 3882905
Lee, J. H. et al. Polymorphisms in HSD17B1: early onset and increased risk of Alzheimer’s disease in women with down syndrome. Curr. Gerontol. Geriatr. Res. 2012, 361218. https://doi.org/10.1155/2012/361218 (2012).
doi: 10.1155/2012/361218
pubmed: 22474448
pmcid: 3310186
Lin, C. C. et al. CoA synthase regulates mitotic fidelity via CBP-mediated acetylation. Nat. Commun. 9, 1039. https://doi.org/10.1038/s41467-018-03422-6 (2018).
doi: 10.1038/s41467-018-03422-6
pubmed: 29531224
pmcid: 5847545
Wojdacz, T. K. & Dobrovic, A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucl. Acids Res. 35, e41. https://doi.org/10.1093/nar/gkm013 (2007).
doi: 10.1093/nar/gkm013
pubmed: 17289753
Kobayashi, N. et al. Development of biomarkers based on DNA methylation in the NCAPH2/LMF2 promoter region for diagnosis of alzheimer’s disease and amnesic mild cognitive impairment. PLoS ONE 11, e0146449. https://doi.org/10.1371/journal.pone.0146449 (2016).
doi: 10.1371/journal.pone.0146449
pubmed: 26742120
pmcid: 4704831
Kobayashi, N. et al. Usefulness of DNA methylation levels in COASY and SPINT1 gene promoter regions as biomarkers in diagnosis of alzheimer’s disease and amnestic mild cognitive impairment. PLoS ONE 11, e0168816. https://doi.org/10.1371/journal.pone.0168816 (2016).
doi: 10.1371/journal.pone.0168816
pubmed: 27992572
pmcid: 5167410
Nagata, T., Shinagawa, S., Nukariya, K., Yamada, H. & Nakayama, K. Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease. Dement. Geriatr. Cogn. Disord. 33, 266–272. https://doi.org/10.1159/000339358 (2012).
doi: 10.1159/000339358
pubmed: 22699449
Petersen, R. C. et al. Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985–1992 (2001).
doi: 10.1001/archneur.58.12.1985
McKhann, G. et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944 (1984).
doi: 10.1212/WNL.34.7.939
Korczyn, A. D. Mixed dementia–the most common cause of dementia. Ann. N. Y. Acad. Sci. 977, 129–134. https://doi.org/10.1111/j.1749-6632.2002.tb04807.x (2002).
doi: 10.1111/j.1749-6632.2002.tb04807.x
pubmed: 12480742
Roman, G. C. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250–260. https://doi.org/10.1212/wnl.43.2.250 (1993).
doi: 10.1212/wnl.43.2.250
pubmed: 8094895
Kida, H. et al. Approach-oriented coping strategy level may be related to volume of the whole hippocampus in the elderly. Psychiatry Clin. Neurosci. https://doi.org/10.1111/pcn.12981 (2020).
doi: 10.1111/pcn.12981
pubmed: 31943584
Folstein, M. F., Folstein, S. E. & McHugh, P. R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatry Res. 12, 189–198 (1975).
doi: 10.1016/0022-3956(75)90026-6
Ronquillo, J. G., Baer, M. R. & Lester, W. T. Sex-specific patterns and differences in dementia and Alzheimer’s disease using informatics approaches. J. Women Aging 28, 403–411. https://doi.org/10.1080/08952841.2015.1018038 (2016).
doi: 10.1080/08952841.2015.1018038
pubmed: 27105335
pmcid: 5110121
Medeiros, A. M. & Silva, R. H. Sex differences in Alzheimer’s disease: where do we stand?. J. Alzheimers. Dis. 67, 35–60. https://doi.org/10.3233/JAD-180213 (2019).
doi: 10.3233/JAD-180213
pubmed: 30530972
Jack, C. R. Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128. https://doi.org/10.1016/S1474-4422(09)70299-6 (2010).
doi: 10.1016/S1474-4422(09)70299-6
pubmed: 20083042
pmcid: 2819840
Hussmann, D. & Hansen, L. L. Methylation-sensitive high resolution melting (MS-HRM). Methods Mol. Biol. 1708, 551–571. https://doi.org/10.1007/978-1-4939-7481-8_28 (2018).
doi: 10.1007/978-1-4939-7481-8_28
pubmed: 29224163